jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Vagina tissue - Large Biopsy 3-6 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Histology of vaginal lesion.

₹666₹951

30% OFF

Vagina Tissue - Large Biopsy 3-6 cm: Comprehensive Medical Guide

  • Why is it done?
    • Test Purpose: A large vaginal tissue biopsy (3-6 cm) is a surgical procedure that removes a significant portion of tissue from the vagina for histopathological examination under a microscope to identify cellular abnormalities, infections, malignancies, or structural disorders.
    • Primary Indications: Suspicion of vaginal cancer or malignancy; evaluation of persistent vaginal lesions, ulcers, or masses; assessment of vaginal intraepithelial neoplasia (VaIN); diagnosis of chronic inflammatory conditions; evaluation of treatment-resistant infections; assessment of vulvovaginal disease; histological confirmation of abnormal imaging or clinical findings.
    • Typical Timing/Circumstances: Performed during gynecological examination or colposcopy when significant tissue abnormalities are visualized; typically conducted in an outpatient surgical center or hospital setting; timing varies based on clinical urgency and patient presentation.
  • Normal Range
    • Normal Histological Findings: Normal stratified squamous epithelium; absence of dysplasia or malignancy; normal vaginal flora; no inflammatory infiltrate; intact basement membrane; normal blood vessel architecture.
    • Result Interpretation: NEGATIVE/BENIGN: Absence of malignancy, dysplasia, or significant pathology; indicates normal tissue architecture and cellular composition. POSITIVE/ABNORMAL: Presence of dysplasia, malignancy, significant inflammation, infection, or structural abnormalities requiring clinical intervention.
    • Units of Measurement: Histopathological classification using the Bethesda System for reporting cervicovaginal cytology when applicable; tissue dimensions measured in centimeters (cm); microscopic findings reported as descriptive pathology with grading scales for dysplasia (CIN I, II, III or VaIN I, II, III).
    • What Normal vs Abnormal Means: NORMAL: Indicates benign tissue without evidence of malignancy, dysplasia, or significant disease; patient typically requires routine follow-up care. ABNORMAL: Suggests presence of pathological changes requiring treatment, closer monitoring, or additional diagnostic procedures; severity determines management approach.
  • Interpretation
    • Detailed Result Interpretation: BENIGN FINDINGS: Normal vaginal epithelium without dysplasia indicates healthy tissue; may show chronic inflammation consistent with common conditions. VAGINAL INTRAEPITHELIAL NEOPLASIA (VaIN): VaIN I (mild dysplasia) - low-grade lesion with potential for progression; VaIN II (moderate dysplasia) - intermediate-grade lesion requiring management; VaIN III (severe dysplasia/CIS) - high-grade lesion with significant malignant potential. MALIGNANCY: Squamous cell carcinoma (most common), adenocarcinoma, or other malignant histologies indicating invasive disease requiring oncological treatment.
    • What Different Results Indicate: Inflammatory changes suggest infection or chronic irritation; infectious organisms may be identified (HPV, fungal, bacterial); atrophic changes indicate hormonal deficiency; metaplastic changes represent normal tissue transformation; dysplastic changes correlate with increased cancer risk proportional to grade severity.
    • Factors Affecting Readings: Specimen quality and adequacy; tissue fixation and processing technique; presence of crush artifact or thermal damage; HPV status and viral load; prior treatment effects; chronic irritant or infectious exposure; hormonal status; immunosuppression; sampling location accuracy; pathologist expertise in gynecological histology.
    • Clinical Significance: Results directly guide clinical management decisions; dysplastic findings necessitate closer surveillance or intervention; malignancy diagnosis initiates oncological treatment planning; benign findings provide reassurance but may require monitoring if clinical suspicion persists; tissue diagnosis supersedes cytology or imaging when conflict exists.
  • Associated Organs
    • Primary Organ System: Lower female reproductive tract; vaginal epithelium and submucosa; external genitalia (vulva); potentially affecting uterus, cervix, and pelvic structures.
    • Associated Medical Conditions: Vaginal cancer (squamous cell, adenocarcinoma, melanoma, sarcoma); cervical intraepithelial neoplasia and cervical cancer; vulvovaginal intraepithelial neoplasia; human papillomavirus (HPV) infection; lichen sclerosus; lichen planus; pemphigoid; chronic vulvovaginitis; vaginal atrophy; endometriosis involving vagina.
    • Diseases This Test Helps Diagnose: Vaginal squamous cell carcinoma; vaginal adenocarcinoma; clear cell adenocarcinoma; melanoma of vagina; vaginal sarcoma; vaginal intraepithelial neoplasia; recurrent or persistent vaginal infections; chronic inflammatory conditions; autoimmune blistering disorders affecting genital tract; post-radiation changes; malignant transformation of premalignant lesions.
    • Potential Complications of Abnormal Results: Malignancy progression leading to metastasis; local tissue invasion; compromise of vaginal function and sexual health; systemic spread to lymph nodes and distant organs; treatment-related morbidity (surgery, chemotherapy, radiation); psychological impact of cancer diagnosis; potential involvement of bladder, rectum, or pelvic structures.
  • Follow-up Tests
    • Additional Tests for Benign Results: Repeat colposcopy if clinical suspicion remains; HPV testing to assess infection status; cervical cytology if not recently performed; imaging (ultrasound, MRI) if structural abnormalities suspected; cultures for recurrent infections; serological testing for autoimmune conditions if indicated.
    • Further Investigations for Dysplasia: HPV genotyping to identify high-risk types; p16/Ki-67 immunohistochemistry for prognostic assessment; colposcopy with targeted biopsies of other suspicious areas; imaging (ultrasound, CT, MRI) to exclude multifocal disease; consultation with gynecological oncologist; consideration of excisional procedures for complete lesion removal.
    • Further Investigations for Malignancy: Staging imaging (CT chest/abdomen/pelvis, MRI pelvis) to assess extent of disease; PET-CT for metastatic evaluation; complete blood count; comprehensive metabolic panel; tumor markers (CEA, CA 19-9) when indicated; assessment of surgical resectability; consultation with gynecological oncology; evaluation for chemotherapy and radiation therapy candidacy.
    • Monitoring Frequency: Benign findings: Annual gynecological examination; colposcopy as clinically indicated. VaIN I: Colposcopy every 6-12 months; consideration of excisional treatment. VaIN II-III: More frequent surveillance (every 3-6 months) or excisional/ablative treatment. Malignancy: Oncology follow-up per treatment protocol; imaging surveillance at defined intervals; assessment for recurrence and long-term complications.
    • Related Complementary Tests: Pap smear/cervical cytology; HPV testing; colposcopy with directed biopsies; vulvar biopsy if external lesions present; sentinel lymph node biopsy for malignancy staging; immunohistochemical studies (p16, Ki-67, p53); molecular studies for HPV typing; imaging studies (ultrasound, CT, MRI); endocervical curettage if cervical involvement suspected.
  • Fasting Required?
    • Fasting Status: NO - Fasting is NOT required for vaginal tissue biopsies as it is a local procedure not requiring general anesthesia for most cases.
    • Medications to Avoid: Antiplatelet agents (aspirin, NSAIDs) - discontinue 5-7 days prior if possible; anticoagulants (warfarin, DOACs) - consult physician regarding timing; herbal anticoagulants (ginkgo, ginseng) - discontinue 1 week prior; topical vaginal medications, creams, douches - avoid 24-48 hours before procedure.
    • Patient Preparation Requirements: Void bladder before procedure; avoid intercourse 24-48 hours prior; schedule procedure not during menstruation if possible (unless clinically urgent); wear comfortable, easily removable clothing; avoid douching 24-48 hours before biopsy; arrange for transportation if local anesthesia/sedation used; inform healthcare provider of all medications and allergies; sign informed consent after discussion of risks/benefits; perform thorough genital hygiene on day of procedure; arrive 15-30 minutes early for registration.
    • Special Instructions: If general anesthesia anticipated, follow NPO (nothing by mouth) guidelines: typically no food/drink 6-8 hours prior; discontinue specific medications as directed by anesthesia team; bring list of current medications and supplements; have responsible adult available for post-procedure transport; plan for 24-48 hours recovery time; anticipate vaginal bleeding/spotting for several days; avoid strenuous activity and intercourse for 2 weeks post-procedure; use over-the-counter pain management if needed; report excessive bleeding, fever, severe pain, or signs of infection to healthcare provider.

How our test process works!

customers
customers